Brought to you by 
Biotech company Aeglea nets $51mm in IPO
13 Apr 2016
Executive Summary
Biotech company Aeglea Biotherapeutics Inc. netted $51mm through the sale of 5.5mm common shares (including 481.9k over-allotment shares; partial exercise) at $10 in its IPO (up-sized from 3.5mm share filing but priced on low end; originally filed for maximum price of $18). The company previously raised $44mm in a Series B round in March 2015 with investments from Lilly Ventures, Novartis Venture Fund, and the University of Texas Horizon Fund.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biotech company Aeglea nets $51mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice